FDA decision on Tysabri pushed back

Share this article:
The FDA’s scheduled March 29 decision on Biogen Idec and Elan’s Tysabri will be delayed by as much as 90 days, the drug makers said this week. An FDA advisory panel ruled unanimously March 9 that Biogen Idec’s multiple sclerosis drug Tysabri should return to the market with safeguards to monitor patient complications. Tysabri marketers pulled the drug in February 2005 after two patients developed progressive multifocal leukoencephalopathy, or PML, a rare and often fatal brain infection. A third patient was later discovered to have PML. Two of the three patients died.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Sales

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.